首页> 外文期刊>International journal of oncology >A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire
【24h】

A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire

机译:一种使用功能化和结构化的医用线从癌症患者外周血体内分离循环肿瘤细胞的新方法

获取原文

摘要

The isolation of circulating tumor cells (CTCs) from the blood of patients afflicted with solid malignant tumors becomes increasingly important as it may serve as a ‘liquid biopsy’ with the potential of monitoring the course of the cancer disease and its response to cancer therapy, with subsequent molecular characterization. For this purpose, we functionalized a structured medical Seldinger guidewire (FSMW), normally used to obtain safe access to blood vessels and other organ cavities, with a chimeric monoclonal antibody directed to the cell surface expressed epithelial cell surface adhesion molecule (EpCAM). This medical device was optimized in vitro and its biocompatibility was tested according to the regulations for medical devices and found to be safe with no noteworthy side effects. Suitability, specificity and sensitivity of the FSMW to catch and enrich CTCs in vivo from circulating peripheral blood were tested in 24?breast cancer or non-small cell lung cancer (NSCLC) patients and in 29 healthy volunteers. For this, the FSMW was inserted through a standard venous cannula into the cubital veins of healthy volunteers or cancer patients for the duration of 30?min. After removal, CTCs were identified by immuno-cytochemical staining of EpCAM and/or cytokeratins and staining of their nuclei and counted. The FSMW successfully enriched EpCAM-positive CTCs from 22 of the 24 patients, with a median of 5.5 (0-50) CTCs in breast cancer (n=12) and 16 (2-515) CTCs in NSCLC (n=12). CTCs could be isolated across all tumor stages, including early stage cancer, in which distant metastases were not yet diagnosed, while no CTCs could be detected in healthy volunteers. In this observatory study, no adverse effects were noted. Evidently, the FSMW has the potential to become an important device to enrich CTCs in vivo for monitoring the course of the cancer disease and the efficacy of anticancer treatment.
机译:从患有实体恶性肿瘤的患者的血液中分离循环肿瘤细胞(CTC)变得越来越重要,因为它可以作为“液体活检”,具有监测癌症病程及其对癌症治疗反应的潜力,以及随后的分子表征。为此,我们对结构化的医学Seldinger导丝(FSMW)进行了功能化,该导丝通常用于获得对血管和其他器官腔的安全通道,并带有针对细胞表面表达的上皮细胞表面粘附分子(EpCAM)的嵌合单克隆抗体。对该医疗器械进行了体外优化,并根据医疗器械法规对其生物相容性进行了测试,结果发现该医疗器械安全无副作用。在24名乳腺癌或非小细胞肺癌(NSCLC)患者和29名健康志愿者中,测试了FSMW从体内循环血液中捕获和富集CTC的适用性,特异性和敏感性。为此,将FSMW通过标准静脉套管插入健康志愿者或癌症患者的肘静脉,持续30分钟。去除后,通过对EpCAM和/或细胞角蛋白进行免疫细胞化学染色并对其细胞核染色来鉴定CTC并计数。 FSMW成功地丰富了24名患者中的22名患者的EpCAM阳性CTC,乳腺癌(n = 12)中位数为5.5(0-50)CTC,非小细胞肺癌(n = 12)中位数为16(2-515)CTC。可以在包括早期癌症在内的所有肿瘤阶段中分离出CTC,其中尚未诊断出远处转移,而在健康志愿者中未检测到CTC。在这项观察性研究中,未发现不良反应。显然,FSMW有潜力成为体内丰富CTC的重要设备,用于监测癌症病程和抗癌治疗的功效。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号